DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Troglitazone in Treating Patients With Liposarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: troglitazone

First Posted Date: 2004-08-12

Last Posted Date: 2017-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 85

Registration Number: NCT00003058

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2009-02-09

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00004164

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2

Conditions: Melanoma (Skin)

Interventions: Biological: autologous dendritic cell-tumor fusion vaccine
Biological: gp100 antigen
Biological: therapeutic autologous dendritic cells

First Posted Date: 2004-06-11

Last Posted Date: 2009-02-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00085397

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Phase 2

Completed

Conditions: Central Nervous System Tumor, Pediatric

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: temozolomide
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: radiation therapy
Drug: Dactinomycin

First Posted Date: 2004-06-11

Last Posted Date: 2015-12-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00084838

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States

and more 9 locations

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: IL-12

First Posted Date: 2004-06-04

Last Posted Date: 2017-04-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00004070

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: bevacizumab
Drug: cyclophosphamide
Drug: methotrexate

First Posted Date: 2004-05-17

Last Posted Date: 2019-05-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT00083031

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myeloma

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: leucovorin calcium
Drug: methotrexate
Drug: methylprednisolone
Procedure: in vitro-treated bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2004-05-03

Last Posted Date: 2017-04-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00005988

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

Phase 3

Conditions: Constipation, Impaction, and Bowel Obstruction
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-05

Last Posted Date: 2018-12-13

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00020605

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

High-dose ICE With Amifostine

Phase 2

Completed

Conditions: Bladder Cancer
Brain and Central Nervous System Tumors
Carcinoma of Unknown Primary
Extragonadal Germ Cell Tumor
Head and Neck Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Sarcoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: Amifostine
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-03-31

Last Posted Date: 2017-01-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00003657

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Trastuzumab

First Posted Date: 2004-03-15

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00004163

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy